O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms

(2014) Anja Maria Schmitt et al.   NEUROENDOCRINOLOGY

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

(2013) Jennifer A. Chan et al.   CANCER

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

(2012) Anna Koumarianou et al.   ENDOCRINE-RELATED CANCER

Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

(2012) Jennifer A. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Streptozocin-based chemotherapy is not history in neuroendocrine tumours

(2012) Katie Weatherstone et al.   Targeted Oncology

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

(2011) Staffan Welin et al.   CANCER

New treatment strategies in advanced neuroendocrine tumours

(2011) Thomas Walter et al.   DIGESTIVE AND LIVER DISEASE

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

(2011) C. J. Auernhammer et al.   GUT

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors

(2010) Thomas Walter et al.   Clinical Colorectal Cancer

NANETS Treatment Guidelines

(2010) Matthew H. Kulke et al.   PANCREAS

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs and p53

(2009) S C Naumann et al.   BRITISH JOURNAL OF CANCER

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of  -catenin and chromosomal instability

(2008) S. Pizzi et al.   ENDOCRINE-RELATED CANCER

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY